Titre : Hydroxymethylglutaryl-CoA reductases

Hydroxymethylglutaryl-CoA reductases : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hydroxymethylglutaryl-CoA reductases : Questions médicales les plus fréquentes", "headline": "Hydroxymethylglutaryl-CoA reductases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-29", "dateModified": "2025-03-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hydroxymethylglutaryl-CoA reductases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "3-Hydroxyacyl-CoA dehydrogenases", "url": "https://questionsmedicales.fr/mesh/D015094", "about": { "@type": "MedicalCondition", "name": "3-Hydroxyacyl-CoA dehydrogenases", "code": { "@type": "MedicalCode", "code": "D015094", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.047.820.150" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent", "alternateName": "Hydroxymethylglutaryl-CoA Reductases, NAD-Dependent", "url": "https://questionsmedicales.fr/mesh/D025781", "about": { "@type": "MedicalCondition", "name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent", "code": { "@type": "MedicalCode", "code": "D025781", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.047.820.150.415.250" } } }, { "@type": "MedicalWebPage", "name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent", "alternateName": "Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent", "url": "https://questionsmedicales.fr/mesh/D025782", "about": { "@type": "MedicalCondition", "name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent", "code": { "@type": "MedicalCode", "code": "D025782", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.047.820.150.415.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Hydroxymethylglutaryl-CoA reductases", "alternateName": "Hydroxymethylglutaryl CoA Reductases", "code": { "@type": "MedicalCode", "code": "D006903", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Russell A DeBose-Boyd", "url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd", "affiliation": { "@type": "Organization", "name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA." } }, { "@type": "Person", "name": "Youngah Jo", "url": "https://questionsmedicales.fr/author/Youngah%20Jo", "affiliation": { "@type": "Organization", "name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA." } }, { "@type": "Person", "name": "George Davey Smith", "url": "https://questionsmedicales.fr/author/George%20Davey%20Smith", "affiliation": { "@type": "Organization", "name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom." } }, { "@type": "Person", "name": "Hiromasa Yoshioka", "url": "https://questionsmedicales.fr/author/Hiromasa%20Yoshioka", "affiliation": { "@type": "Organization", "name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan." } }, { "@type": "Person", "name": "Kenji Ohgane", "url": "https://questionsmedicales.fr/author/Kenji%20Ohgane", "affiliation": { "@type": "Organization", "name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Steatotic liver disease associated with 2,4-dienoyl-CoA reductase 1 deficiency.", "datePublished": "2024-09-14", "url": "https://questionsmedicales.fr/article/39277655", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41366-024-01634-z" } }, { "@type": "ScholarlyArticle", "name": "Dynamic lid domain of Chloroflexus aurantiacus Malonyl-CoA reductase controls the reaction.", "datePublished": "2023-11-10", "url": "https://questionsmedicales.fr/article/37952891", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biochi.2023.11.003" } }, { "@type": "ScholarlyArticle", "name": "Chronic Anti-HMG-CoA Reductase Positive Necrotizing Myositis With Remote Exposure to Statins.", "datePublished": "2023-06-17", "url": "https://questionsmedicales.fr/article/37465805", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7759/cureus.40552" } }, { "@type": "ScholarlyArticle", "name": "Identification of a cinnamoyl-CoA reductase from Cinnamomum cassia involved in trans-cinnamaldehyde biosynthesis.", "datePublished": "2024-04-30", "url": "https://questionsmedicales.fr/article/38687380", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00425-024-04419-w" } }, { "@type": "ScholarlyArticle", "name": "Direct binding to sterols accelerates endoplasmic reticulum-associated degradation of HMG CoA reductase.", "datePublished": "2024-02-06", "url": "https://questionsmedicales.fr/article/38319967", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1073/pnas.2318822121" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D010088" }, { "@type": "ListItem", "position": 5, "name": "Alcohol oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D000429" }, { "@type": "ListItem", "position": 6, "name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D064430" }, { "@type": "ListItem", "position": 7, "name": "3-Hydroxyacyl-CoA dehydrogenases", "item": "https://questionsmedicales.fr/mesh/D015094" }, { "@type": "ListItem", "position": 8, "name": "Hydroxymethylglutaryl-CoA reductases", "item": "https://questionsmedicales.fr/mesh/D006903" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hydroxymethylglutaryl-CoA reductases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-30", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases", "description": "Comment diagnostiquer une dysfonction des réductases ?\nQuels examens sont recommandés pour évaluer les réductases ?\nLes tests génétiques sont-ils utiles ?\nQuels symptômes indiquent un problème avec les réductases ?\nComment évaluer l'activité des réductases ?", "url": "https://questionsmedicales.fr/mesh/D006903?page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases", "description": "Quels sont les symptômes d'une hypercholestérolémie ?\nComment se manifeste une maladie liée aux réductases ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours présents ?\nQuels autres symptômes peuvent survenir ?", "url": "https://questionsmedicales.fr/mesh/D006903?page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases", "description": "Comment prévenir les problèmes liés aux réductases ?\nLe tabagisme influence-t-il les réductases ?\nL'alcool a-t-il un impact sur le cholestérol ?\nLes contrôles médicaux réguliers sont-ils importants ?\nQuels aliments privilégier pour la santé des réductases ?", "url": "https://questionsmedicales.fr/mesh/D006903?page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases", "description": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?\nY a-t-il des traitements non médicamenteux ?\nComment les statines agissent-elles ?\nLes traitements sont-ils efficaces à long terme ?\nQuels effets secondaires peuvent survenir ?", "url": "https://questionsmedicales.fr/mesh/D006903?page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hydroxymethylglutaryl-CoA reductases", "description": "Quelles complications peuvent survenir avec une dyslipidémie ?\nComment l'athérosclérose est-elle liée aux réductases ?\nLes maladies hépatiques sont-elles une complication ?\nQuels risques cardiovasculaires sont associés ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D006903?page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases", "description": "Quels sont les principaux facteurs de risque ?\nL'hérédité joue-t-elle un rôle ?\nLe stress influence-t-il les niveaux de cholestérol ?\nL'âge est-il un facteur de risque ?\nLes maladies chroniques influencent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D006903?page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des réductases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins mesurant les niveaux de cholestérol et des enzymes hépatiques sont effectués." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour évaluer les réductases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Une échographie abdominale et des tests de fonction hépatique peuvent être recommandés." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent identifier des mutations génétiques affectant les réductases." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec les réductases ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de cholestérol et des maladies cardiovasculaires peuvent indiquer un problème." } }, { "@type": "Question", "name": "Comment évaluer l'activité des réductases ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des hydroxyméthylglutaryl-CoA réductases." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une hypercholestérolémie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs thoraciques, fatigue et problèmes cardiaques." } }, { "@type": "Question", "name": "Comment se manifeste une maladie liée aux réductases ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut se manifester par des dépôts de cholestérol dans les artères et des douleurs." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des xanthomes peuvent apparaître, indiquant une accumulation de lipides." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques malgré des niveaux élevés de cholestérol." } }, { "@type": "Question", "name": "Quels autres symptômes peuvent survenir ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la vision et des douleurs abdominales peuvent également se manifester." } }, { "@type": "Question", "name": "Comment prévenir les problèmes liés aux réductases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et l'exercice régulier aident à maintenir un bon cholestérol." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il les réductases ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque de dyslipidémie et de maladies cardiovasculaires." } }, { "@type": "Question", "name": "L'alcool a-t-il un impact sur le cholestérol ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une consommation excessive d'alcool peut aggraver les niveaux de cholestérol." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils permettent de détecter précocement les anomalies du cholestérol." } }, { "@type": "Question", "name": "Quels aliments privilégier pour la santé des réductases ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les aliments riches en fibres, comme les fruits et légumes, sont bénéfiques." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les statines sont couramment prescrites pour réduire le cholestérol sanguin." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des changements de mode de vie comme l'alimentation et l'exercice sont recommandés." } }, { "@type": "Question", "name": "Comment les statines agissent-elles ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Elles inhibent l'hydroxyméthylglutaryl-CoA réductase, réduisant ainsi la production de cholestérol." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces à long terme ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, avec un suivi régulier, les traitements peuvent maintenir des niveaux de cholestérol sains." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs musculaires et des troubles digestifs sont des effets secondaires possibles." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dyslipidémie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent les maladies cardiaques, les AVC et l'athérosclérose." } }, { "@type": "Question", "name": "Comment l'athérosclérose est-elle liée aux réductases ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une production excessive de cholestérol due à des réductases dysfonctionnelles peut provoquer l'athérosclérose." } }, { "@type": "Question", "name": "Les maladies hépatiques sont-elles une complication ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une accumulation de lipides peut entraîner des maladies hépatiques comme la stéatose." } }, { "@type": "Question", "name": "Quels risques cardiovasculaires sont associés ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux élevés de cholestérol augmentent le risque de crises cardiaques et d'AVC." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'obésité, le tabagisme, l'inactivité physique et une mauvaise alimentation." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de dyslipidémie augmentent le risque de problèmes liés aux réductases." } }, { "@type": "Question", "name": "Le stress influence-t-il les niveaux de cholestérol ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à des niveaux de cholestérol élevés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de dyslipidémie augmente avec l'âge, surtout après 45 ans." } }, { "@type": "Question", "name": "Les maladies chroniques influencent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme le diabète augmentent le risque de dyslipidémie et de complications." } } ] } ] }

Sources (1524 au total)

Steatotic liver disease associated with 2,4-dienoyl-CoA reductase 1 deficiency.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is considered multifactorial with a number of predisposing gene polymorphisms known.... The occurrence of MASLD in 7 and 10 year old siblings, one without classical risk factors and one with type 2 diabetes suggested a monogenic etiology and prompted next-generation sequencing. Exome seq... Two siblings have hepatomegaly, elevated serum transaminase activity, and steatosis and harbor a homozygous DECR1 splice-site variant, c.330+3A>T. The variant caused DECR1 transcript decay. Immunostai... These patients may represent the first individuals with DECR1 deficiency, then defining within MASLD an autosomal-recessive entity, well corresponding to the reported steatotic liver disease in Decr1 ...

HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis.

Disseminated Intravascular Coagulation (DIC) is a syndrome of dysregulated coagulation. Patients with sepsis are at increased risk for DIC. HMG-CoA Reductase Inhibitors (Statins) are primarily used as... To evaluate whether statins may be protective against the development of DIC, we conducted a multi-center, retrospective case-control study where 86,638 critically ill patients admitted to the ICU wit... 2236 patients would develop DIC compared to 84,402 who did not. The use of any statin was associated with a reduced likelihood for developing DIC (odds ratio [OR], 0.69; 95% CI, 0.61-0.78). This was o... The use of moderate and high intensity statins was associated with a significantly reduced odds of developing DIC in critically ill patients with sepsis. This present study may be the first to suggest...

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Cardiovascular disease is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), and the absolute risk of cardiovascular events is similar to people with coronar... To evaluate the benefits and harms of statins compared with placebo, no treatment, standard care or another statin in adults with CKD not requiring dialysis.... We searched the Cochrane Kidney and Transplant Register of Studies up to 4 October 2023. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, th... Randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of statins with placebo, no treatment, standard care, or other statins, on death, cardiovascular events, kidney function, t... Two or more authors independently extracted data and assessed the study risk of bias. Treatment effects were expressed as mean difference (MD) for continuous outcomes and risk ratios (RR) for dichotom... We included 63 studies (50,725 randomised participants); of these, 53 studies (42,752 participants) compared statins with placebo or no treatment. The median duration of follow-up was 12 months (range... Statins reduce death and major cardiovascular events by about 20% and probably make no difference to stroke or kidney failure in people with CKD not requiring dialysis. However, due to limited reporti...

Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with significant clinical implications. The potential influence of lipid-lowering therapies, specifically PCSK9 inhibitors (PCSK9i) and HMG-C... Utilizing publicly available, summary-level genome-wide association study (GWAS) data, we employed single-nucleotide polymorphisms (SNPs) associated with lower LDL-C levels as instruments for gene-sim... Genetically predicted inhibition of PCSK9 demonstrated a reduced risk of AF, with an odds ratio (OR) of 0.92 (95% CI: 0.85 to 0.99, p=0.01) using the inverse variance weighted (IVW) method. In contras... Our MR study suggests that genetically predicted inhibition of PCSK9, but not HMG-CoA reductase, is associated with a lower risk of AF. These findings provide evidence for a causal protective effect o...

Association between Genetically Proxied Inhibition of HMG-CoA Reductase and Age at Onset of Huntington's Disease.

Previous studies have found that statins may play a potential role in the age at onset (AAO) of Huntington's disease (HD). We performed this Mendelian randomization (MR) study to assess the associatio... Single-nucleotide polymorphisms (SNPs) in HMG-CoA reductase associated with LDL cholesterol in a genome-wide association study (GWAS) analysis were used. The summary data of residual AAO of HD were ob... Genetically proxied plasma LDL cholesterol (β = 0.039, 95% CI = -0.454 to 0.531) and HMG-CoA reductase inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL cholesterol (β = -2.228, 95% CI... The plasma LDL cholesterol levels and the reduction of plasma LDL cholesterol levels by the inhibition of HMG-CoA reductase (i.e., statins) were not associated with the age of HD onset....